Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Peptide-liganded G protein-coupled receptors (GPCRs) are increasingly important drug targets, particularly within the rhodopsin and Class B structural classes.
• While the physiology of some peptide-GPCRs is well-understood, translating peptide ligands into orally available, stable drugs remains challenging.
• Peripheral peptide administration shows efficacy in metabolic disorders, indicating non-peptide drugs aren't always necessary.

Purpose of the Study:

• To review recent advancements in GPCR structure, signaling, and genetic analyses of peptide and peptide receptor knockouts.
• To explore how understanding peptide-GPCR roles in mammalian adaptive behaviors can inform drug target identification.
• To highlight progress in developing therapeutics for neurological and psychiatric disorders targeting specific peptide-GPCRs.

Main Methods:

• Analysis of recent GPCR structure and intracellular signaling studies.
• Examination of genetic knockout phenotypes in animal models for peptide and peptide receptors.
• Review of therapeutic progress for key peptide ligands and their GPCRs.

Main Results:

• Research converges on a better understanding of peptide-facilitated adaptive behaviors in mammals.
• Identified pathways for translating peptide-GPCR knowledge into drug targets for various diseases.
• Spectrum of progress assessed for peptide receptors linked to existing and emerging therapeutics.

Conclusions:

• Advances in GPCR research offer new strategies for developing drugs targeting peptide receptors.
• Understanding peptide-GPCR signaling is crucial for addressing neurological and psychiatric illnesses.
• The study highlights the therapeutic potential of targeting peptide receptors for conditions including obesity, addiction, and neurodegenerative diseases.